chemosensitive relapsed and refractory NHL. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The success of autotransplantation in advanced stage patients has led to its use as consolidation therapy for patients with poor One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) prognostic features in first complete remission. 16, 17 This approach, however, may increase the risk of myelodysplawere evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose sia (MDS) and acute myeloid leukemia (AML). 
Treatment alternatives for relapsed or refractory lymtherapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) folphoma now include conventional-dose chemotherapy, allogeneic marrow transplantation, conjugated or unconjugated lowed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the lymphocytotoxic anti-B cell monoclonal antibody therapy, anti-idiotype immunotherapy, and purged autologous marentire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years row grafting making the selection of treatment for individual patients complex. [20] [21] [22] [23] [24] Long-term follow-up of auto-(range 0-7.5 years). For patients entering with minimal disease (defined as all areas р2 cm), the 5-year EFS was transplant recipients to assess treatment outcomes and to identify important prognostic factors could facilitate the 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on rational assignment of patients to alternative therapies. This report details the long-term follow-up of 136 conentry and administration of involved-field XRT posttransplant were significantly associated with improved secutive patients transplanted for relapsed or refractory NHL performed at a single institution using primarily the EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-carmustine/BCNU, etoposide, cytarabine, cyclophosphamide (BEAC) preparative regimen. An analysis of the first day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to 53 NHL patients was reported previously, 6 but this report includes an additional 83 patients and updates all aspects reduce the high rate of relapse (50-60%) following autotransplantation for relapsed or refractory NHL.
of therapy by more than 3 years. Keywords: lymphoma; autotransplantation; radiotherapy; prognostic factors
Patients and methods
Patients CHOP and its variants remain the mainstay of therapy for advanced, intermediate-to high-grade lymphoma, producOne hundred and thirty-six patients underwent autotransing long-term disease remissions or cures in about 35% of plantation between November 1988 and April 1996. patients.
1,2 Of the patients who do not obtain a complete Characteristics of the study patients are given in Table 1 . remission after initial therapy or who relapse, less than 5%
Patients were treated with one to three cycles of dexameof patients treated with a variety of conventional-dose regithasone, high-dose cytarabine, and cisplatin or carboplatin mens avoid relapse beyond 3 years. [3] [4] [5] High-dose chemo-(DHAP), 25 or one of several other regimens, until a comtherapy followed by autologous marrow or blood stem cell plete response was obtained or there was no significant rescue has become the standard treatment for patients with interval change on successive radiographic or clinical examinations. and engraftment kinetics for these patients were described previously. 26 For the 56 patients who received mobilized PBSC, most were collected after myelosuppression using 3 response to salvage therapy. Some patients were not evaluable for response to salvage therapy because they were g/m 2 of cyclophosphamide over 2 days followed by marrow stimulation with GM-CSF, G-CSF, G + GM-CSF, or PIXYtransplanted immediately in relapse or did not have informative radiographic studies. After completion of sal-321. 27 The median number of mononuclear cells collected for mobilized patients approximated 2.4 × 10 8 /kg body vage therapy, and prior to autotransplantation, patients were stratified into two groups: minimal disease or bulky disease.
weight and the median CFU-GM approximated 2 × 10 4 /kg. Minimal disease was defined as: (1) All nodal areas р2 cm in maximal diameter; (2) extranodal disease confined to a Supportive care single organ or tissue containing a single tumor р2 cm in maximal diameter; (3) marrow involvement р20% of marPatients received care in individual rooms equipped with high efficiency particulate air (HEPA) filtration units. row cellularity; (4) no active CNS involvement. All other patients were considered to have bulky disease. In partiPatients received prophylactic acyclovir for positive herpes simplex virus (HSV) serologies. Empiric broad-spectrum cular, patients with diffuse or multifocal involvement (у2 sites) of a single extranodal tissue or any measurable antibacterial agents (generally a semisynthetic penicillin and aminoglycoside) were administered for neutropenic involvement of more than one extranodal tissue were considered to have bulky disease. All patients gave written febrile episodes. Amphotericin B was begun if patients became febrile a second time or if the initial fever (у38°C) informed consent to undergo autotransplantation.
persisted despite 48 to 72 h of antibacterial therapy. Patients were transfused with irradiated blood products to Preparative regimens keep the hematocrit у25 ml/dl and the platelet count у20 000/l. Beginning in April 1991, patients received Of the 136 patients in this series, 117 (87%) received the BEAC conditioning regimen: BCNU 300 mg/m 2 on day −7, hematopoietic growth factors after stem-cell infusion. Fifteen patients participated in a randomized, placebo-conetoposide 100 mg/m 2 twice daily on days −6 to −3, cytarabine 100 mg/m 2 twice daily on days −6 to −3, and cyclotrolled study in which 11 were randomized to receive one of two GM-CSF doses (5 g/kg or 10 g/kg) intravenously phosphamide 35 mg/kg on days −6 to −3. One patient received BEAM in which melphalan 140 mg/m 2 was given over 2 h beginning on day 0. Subsequent patients received GM-CSF or G-CSF at a dose of 5 g/kg subcutaneously or intravenously over 2 h beginning on day 0 or day 5 following stem cell infusion.
Post-transplant involved-field radiation
Beginning in September 1990, 51 patients who entered transplantation with clinical or radiologic evidence of disease received post-transplant involved-field radiotherapy. These treatments were usually administered within 4 to 8 weeks of discharge and were recommended even if disease areas disappeared after transplant. Treatment was delayed until the neutrophil count exceeded 1000/l and transfusions were no longer required. The following protocol the BEAC regimen and one received TBI/cyclophosphgroup were re-evaluated after receiving 30 Gy by physical amide. All four patients have died, three of whom were examination and imaging, and if the tumor size had free of lymphoma at the time of death. Leukemia therapy decreased by this point, then an additional 6-10 Gy was was unsuccessful for two patients while a third patient had administered based on tissue tolerance. The rationale for a 6-month remission after induction therapy. The fourth this step-wise approach is that a stable mass may be largely patient received no additional therapy and died from AML fibrotic, while a responding mass may contain significant and relapsed lymphoma. viable disease.
Sixty-six patients relapsed at a median of 4 months posttransplant. Six relapses occurred after 2 years at 2, 2.2, 2.6, Statistical methods 2.7, 3.8 and 5.3 years of follow-up. An additional patient died from choledochocarcinoma at 3.1 years of follow-up For survival analysis, an event was defined as death from while apparently free of lymphoma. Forty-one relapses any cause or disease relapse or progression. In addition, (62%) involved previous sites of disease. patients who developed advanced MDS or AML post-transplant were considered to have events. The product limit estimator was used to generate survival curves. 28 The logPrognostic factors rank test was used to compare groups. The Cox pro- Table 3 shows the variables tested for prognostic signifiportional hazards model was used in a multivariate analysis cance. The only significant predictor of improved EFS was of the data. 28 All P values are two-sided. SAS (SAS Instidisease status at transplant. As shown in Figure 2 , the 5-tute, Cary, NC, USA) was used to generate the survival year Kaplan-Meier EFS was 40% for the 78 patients curves and calculate the log-rank statistics. BMDP2L entering with minimal disease and 26% for the 58 patients (University of California Press, Berkeley, CA, USA) was entering with bulky disease (P = 0.0004). Marginally sigused to perform the Cox regressions.
nificant favorable factors were female gender and a positive response to pretransplant cytoreductive therapy. Several factors were not significantly associated with outcome Results including patient age, histology, stem cell source, and transplant regimen. Of 14 patients who were aged у60 at the Survival time of transplant, 10 (70%) including a 71-year-old female survived event-free at a median follow-up of 2.8 years The 5-year Kaplan-Meier EFS for the 136 patients was 34% (95% CI: 24-44%) (Figure 1) . The median follow-up (range 0.8-4.6 years).
In Table 4 , patients with bulky disease were segregated of the 55 event-free survivors was 2.8 years (range 1 month-7.5 years). Eight patients survived event-free according to the longest dimension of the largest pre-transplant nodal area or according to the major site(s) of extranobeyond the 5-year mark.
Of the 136 patients, 15 (11%) died from events related dal involvement. These data suggest that prolonged eventfree survival can still be obtained in a few patients with to the transplant procedure. As shown in Table 2 , six events occurred before 100 days post-transplant yielding a 100-large residual masses. Indeed, two patients with a 6 cm or 10 cm mediastinal mass have survived event-free at 4.0 and day treatment-related mortality of 4.4% while nine events occurred after 100 days. For the 71 patients transplanted 4.6 years of follow-up, respectively. Among the patients who entered with bulky extranodal disease, three of five since January 1993, the 100-day mortality rate was 3%. Among the nine patients with late events, four patients patients with primarily marrow or spleen involvement have survived event-free at 0.5, 0.9, and 2.4 years of follow-up. (3%) developed advanced, transfusion-dependent myelodysplasia or acute myeloid leukemia at 1.0, 1.1, 2.0 and 4.2
The latter patient had 50% involvement of bone marrow 886 The LDH levels of patients with bulky disease surviving event-free were compared to those of patients who relapsed Total 15 4 (26%) early (р100 days) after the transplant procedure. (18) 1 (6) 1 (6) (cyclophosphamide, vincristine, prednisone). Seventeen (n = 17) patients (85%) also had minimal disease at the time of
Relapsed р100 days 4 (18) 8 (36) 4 (18) 6 (27) transplant. On subgroup analysis: four of six patients with (n = 22) diffuse mantle cell lymphoma have survived event-free at 0.3, 2.6, 5.4 and 5.7 years of follow-up; two of five patients LDH levels given as ratio to upper limit of normal (X-ULN). Normal (NML) includes levels up to 1.1 X ULN. 2 square test of normal vs with nodular mixed cell lymphoma are surviving event-free abnormal levels for the two groups is significant (P = 0.0001).
at 2.6 and 3.0 years of follow-up, the latter patient having been previously treated for a large-cell transformation; and two of nine patients (22%) with nodular small cleaved cell 
Effect of post-transplant radiotherapy
The multivariate analysis revealed significantly better EFS in the univariate analysis and three other clinically relevant for patients who received post-transplant involved-field variables (post-transplant XRT, stem cell source, and radiotherapy. The relation of post-transplant involved-field histology) were entered into a Cox proportional hazards radiotherapy to outcome is shown in Figure 4 where model to identify factors jointly associated with EFS. Salpatients are stratified according to disease status on entry. vage response was not included due to the large number of Of the 78 patients entering with minimal disease, the 21 patients considered unevaluable for this characteristic. The who received post-transplant XRT had a 3-year EFS of 55 results of this multivariate analysis are shown in Table 6 .
vs 47% for the 57 untreated patients (P = 0.63). Of the 58 As expected, minimal disease on entry was independently patients transplanted with bulky disease, the 30 patients associated with improved EFS. Post-transplant radiotherapy who received post-transplant XRT had a 3-year EFS of 35 was also significantly associated with outcome.
vs 16% for the 28 untreated patients (P = 0.04). Since patients were not allocated randomly to post-transplant radiotherapy other factors may have contributed to the Effect of histology observed differences. One potential reason for the apparent Transplants were performed on 20 patients who had previously received extensive treatment for low-grade lymphomas. As shown in Figure 3 , the 5-year EFS of 35% for benefit of post-transplant XRT may be that patients with The role of autotransplantation for low-grade lymphoma remains unclear. 32 Initial reports on this subject demonearly events (relapses or treatment-related mortality) did not survive long enough to receive radiotherapy but would be strated high event-free survival rates early after transplant 33-35 but a pattern of continued relapses has been counted as untreated patients. To minimize the impact of this potential bias, the survival analysis shown in Figure 4 recognized in some series after longer follow-up. 36 Our results compare favorably with those reported for patients was repeated after excluding patients with early events (р day 50). After this adjustment, patients with bulky disease with relapsed/refractory indolent lymphomas treated with conventional-dose fludarabine/mitoxantrone/dexamewho received post-transplant XRT showed a 3-year EFS of 39 vs 24% for the untreated patients but this difference was thasone, 37 in which the 2.5 year failure-free survival approached 20% for complete responders and was Ͻ10% no longer significant (P = 0.32), possibly due to the smaller number of patients in each group. Of the 51 patients treated, for partial responders, with no survival plateaus evident for either group. The outcome for the group of 20 patients one patient who received 30 Gy of involved field radiation for bulky mediastinal disease died from pneumonitis transplanted with low-grade lymphoma in the present study may be due in part to its composition. Six of the 20 patients shortly after completion of therapy.
had diffuse mantle cell lymphoma while five had nodular mixed lymphoma, subtypes that have a more aggressive Discussion clinical course and may respond better to chemotherapy. The 3-and 5-year Kaplan-Meier event-free survivals for This study based on 136 patients and a median follow-up of almost 3 years for the 55 event-free survivors, confirms patients transplanted with minimal disease were 49 and 40%, respectively, and administration of post-transplant the observations made in a previous analysis of the first 53 patients. 6 The 3-year Kaplan-Meier EFS was again 40%, radiotherapy did not seem to improve the outcome for this subgroup. Patients transplanted with minimal disease may but decreased to 34% at 5 years due to a small number of relapses and second malignancies which occurred after the benefit from post-transplant immunotherapy using interleukin-2, ␣-interferon, or anti-CD19 or anti-CD20 monoclonal 3-year mark. Disease status on entry was the most significant predictor of outcome on univariate analysis while antibodies. [40] [41] [42] [43] [44] In summary, BEAC is an effective preparative regimen female gender and a positive response to pre-transplant cytoreductive therapy were marginally associated with with low treatment-related mortality for patients autografted for relapsed or refractory lymphoma. This longimproved EFS. The multivariate model indicated that minimal disease on entry and administration of post-transplant term follow-up study supports previous reports suggesting that minimal disease on entry is an important favorable involved-field radiotherapy were independently associated with improved EFS, while female gender was again marprognostic factor. A small but significant proportion of patients with bulky disease who lack additional adverse ginally associated with outcome. The reason for the trend toward better outcome for female patients in this study is prognostic factors also show durable event-free survival particularly after involved-field radiotherapy. Novel stranot clear.
A significant proportion of patients with bulky disease tegies are needed to reduce the rate of relapse post-transplant for all patients, including those transplanted with have remained event-free with long follow-up, including six patients who entered with masses у5 cm in diameter. minimal disease. Among the patients with bulky disease, non-hematopoietic extranodal involvement and markedly elevated pre-transAcknowledgements plant LDH levels were associated with a higher risk of relapse. The elevated LDH levels in the early relapse group This work was supported in part by a Fellowship from the James may reflect increased tumor growth rate or necrosis, factors P Wilmot Foundation (APR) and presented in part at the Annual which may affect the response to high-dose therapy. 
